Alzamend Neuro Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $1.37
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 18.9K
About
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Quick stats
Shares outstanding4.8M
Computed float4.7M
Float / shares97.3%
Cash runway (months)17.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001677077
Websitehttps://www.alzamend.com
AI Summary
AI-generated1/6
minorbullishregulatory
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro (Nasdaq: ALZN) received a Compliance Notice dated September 14, 2026 confirming it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Rule, and the matter is now closed.
The company evidenced stockholders' equity of $5,802,680 in its 10-Q for the quarter ended July 31, 2026, filed September 10, 2026, versus the $2.5 million minimum required.
Alzamend had been notified on March 20, 2026 that it failed continued-listing standards; its remediation plan was accepted and it was granted until September 16, 2026 to regain compliance.
CEO Stephan Jackman said the company's full focus returns to advancing AL001 through four Phase II clinical trials in partnership with Massachusetts General Hospital, with the bipolar disorder cohort initiated in April 2026 and Alzheimer's, MDD, and PTSD cohorts to follow.
Red flags
- stockholders' equity of $5.8M is a thin cushion for a cash-burning clinical-stage company; equity-rule deficiency could recur
- company spent nearly six months on a Nasdaq compliance plan after failing multiple continued-listing standards in March 2026